CN107536055A - A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment - Google Patents
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment Download PDFInfo
- Publication number
- CN107536055A CN107536055A CN201710975550.9A CN201710975550A CN107536055A CN 107536055 A CN107536055 A CN 107536055A CN 201710975550 A CN201710975550 A CN 201710975550A CN 107536055 A CN107536055 A CN 107536055A
- Authority
- CN
- China
- Prior art keywords
- parts
- haematococcus pluvialis
- astaxanthin
- infertile
- auxiliary treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Non-Alcoholic Beverages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Disclosed by the invention is a kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, including following components：Astaxanthin In Haematococcus Pluvialis, chalybeate, folic acid, DHA；Haematococcus pluvialis spore powder with crushed sporoderm or Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powder, chalybeate, folic acid, DHA, sweetener, acid, acesulfame potassium, flavoring essence；Haematococcus pluvialis spore powder with crushed sporoderm or Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powder, chalybeate, folic acid, DHA, sweetener, magnesium stearate, acid, flavoring essence, the present invention can effectively reduce the response to oxidative stress of sperm ovum, improve the vigor of sperm ovum, avoid teratospermia, be advantageous to the growth of sperm, reproductive organs inflammation is mitigated or eliminated, improves fecundity；Formula is simple, easily manufactured, can be made into a variety of formulations, absorption efficiency is high, and has no side effect to human body.
Description
Technical field
The present invention relates to a kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, belongs to food, protects
Health food field.
Background technology
At present, due to reasons such as job and life stress, environmental pollution and the bad habits of individual, it causes compatriots Asia
Healthy ratio expands day by day, and larger negative effect is generated to the fecundity of the mankind so that the infertile rate of the mankind occupies
It is high not under, according to incompletely statistics, the infertile patient in the whole nation has a strong impact on the happy family life of compatriots more than 40,000,000 people at present,
And currently on the market have improve fecundity product, long-term use of side effect is obvious, such as have higher dependence, it is necessary to
Long-term use, so being badly in need of one kind has Small side effects, the response to oxidative stress of sperm ovum can be effectively reduced, improves sperm
The quality and vigor of ovum, avoid teratospermia, are advantageous to the growth of sperm and the skills such as reproductive organs inflammation are mitigated or eliminated
The product of art feature.
The content of the invention
In order to solve above-mentioned prior art problem, the present invention provides anti-with the oxidative stress for effectively reducing sperm ovum
Should, the quality and vigor of sperm ovum are improved, teratospermia is avoided, is advantageous to the growth of sperm, reproductive organs is mitigated or eliminated
Inflammation, improve a kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment of the technical characterstics such as fecundity.
To achieve these goals, the present invention is achieved by the following technical solutions：
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：2-20 part Astaxanthin In Haematococcus Pluvialis, 1-10 part chalybeates, 0.2-0.8 part folic acid, 20-200 parts DHA.
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：40-4000 part haematococcus pluvialis spore powder with crushed sporoderm of water solubility processing, 1-10 part chalybeates, 0.2-0.8 part folic acid,
20-200 parts DHA, 40-9900 part sweetener, 0.05-10 part acids, 0.01-3 part acesulfame potassiums, 0.1-20 part flavoring essences.
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：20-1000 part Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 1-10 part chalybeates, 0.2-0.8 part folic acid, 20-
200 parts of DHA, 60-9900 part sweetener, 0.05-10 part acids, 0.01-3 part acesulfame potassiums, 0.1-20 part flavoring essences.
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：40-4000 part haematococcus pluvialis spore powder with crushed sporoderm of water solubility processing, 1-10 part chalybeates, 0.2-0.8 part folic acid,
20-200 parts DHA, 120-4900 part sweetener, 0.2-50 part magnesium stearates, 0.5-10 part acids, the edible perfume of 0.1-10 parts
Essence.
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：20-1000 part Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 1-10 part chalybeates, 0.2-0.8 part folic acid, 20-
200 parts of DHA, 120-4900 part sweetener, 0.2-50 part magnesium stearates, 0.5-10 part acids, 0.1-10 part flavoring essences.
As a preferred embodiment, the chalybeate be ferrous sulfate, ferrous lactate, any of ferrous fumarate or two kinds with
On.
As a preferred embodiment, the acid is any of citric acid, lactic acid, malic acid or two or more, it is described
Sweetener is any of D-sorbite, xylitol, acesulfame potassium, Abbas's sweet tea or two or more.
As a preferred embodiment, it can be made into solid beverage and tablet after the mixing of each component.
Beneficial effects of the present invention：The response to oxidative stress of sperm ovum can be effectively reduced, improves the matter of sperm ovum
Amount and vigor, avoid teratospermia, and reproductive organs inflammation is mitigated or eliminated, and improve fecundity；Formula is simple, easily manufactured,
Absorption efficiency is high；It is adapted to long-term adjuvant therapy, has no side effect to human body.
Astaxanthin In Haematococcus Pluvialis possess anti-oxidant, scavenging activated oxygen, enhancing cytothesis ability, anti-inflammatory it is anti-infective,
Sperm quantity and quality and other effects are improved, Human sperm cells are very sensitive to oxidative damage, easily receptor 1 activity oxygen injury, and oxidation should
Swash reduce sperm quality it is infertile so as to cause, Astaxanthin In Haematococcus Pluvialis can protect the cell membrane of sperm from oxygen
Change so as to reduce these harm, improve pregnancy chance, meanwhile, Astaxanthin In Haematococcus Pluvialis can also effectively help people to nurse one's health body
Body, make people more healthy more vibrant from whole body.
Folic acid is a kind of water soluble vitamin, and the necessary material of DNA synthesis, and folic acid deficiency can influence DNA synthesis, from
And fission process is damaged, especially for the cell and tissue of those high score rates, such as with the essence of high speed synthetic DNA
Daughter cell, folic acid can avoid teratospermia and sperm motility from declining, and be advantageous to sperm growth, women is about to begin suitable before pregnancy
Supplement of folic acid is measured, is advantageous to become pregnant.
Chalybeate, iron are the essential trace elements of the human bodys, require supplementation with iron during forepart pregnant women.
DHA (docosahexaenoic acid) is a kind of to the very important unrighted acid of human body, and it is that nervous system is thin
Intracellular growth and a kind of main component of maintenance, are the important composition compositions of brain and retina, the content in human brain cortex
Up to 20%, proportion is maximum in eye retina, accounts for 50%, most important to tire infant intelligence and visual acuity.
Embodiment
Below by way of specific embodiment, the present invention is further illustrated, but embodiments of the present invention not by
The limitation of following examples.
Embodiment 1
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：The haematococcus pluvialis spore powder with crushed sporoderm of 300 parts of water-soluble processing, 4 parts of chalybeates, 0.2 part of folic acid, 100 parts of DHA,
2589 parts of D-sorbites, 3 parts of citric acids, 0.6 part of acesulfame potassium, 3 parts of flavoring essences.
4 parts of chalybeates, 0.2 part of folic acid, 100 parts of DHA, 2589 parts of D-sorbites, 3 parts of citric acids, 0.6 part of acesulfame potassium are mixed
Close, stir and evenly mix, add 3 parts of flavoring essences and 300 parts of haematococcus pluvialis spore powder with crushed sporoderm by water-soluble processing stir, be mixed
Close and mix, sterilize, solid beverage is made.
Embodiment 2
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：The haematococcus pluvialis spore powder with crushed sporoderm of 800 parts of water-soluble processing, 10 parts of chalybeates, 0.5 part of folic acid, 200 parts of DHA,
6000 parts of D-sorbites, 7.5 parts of citric acids, 1.5 parts of acesulfame potassiums, 7.5 parts of flavoring essences.
By 10 parts of chalybeates, 0.5 part of folic acid, 200 parts of DHA, 6000 parts of D-sorbites, 7.5 parts of citric acids, 1.5 parts of acesulfame potassiums
Mix, stir and evenly mix, add 7.5 parts of flavoring essences and 800 parts of haematococcus pluvialis spore powder with crushed sporoderm by water-soluble processing stir
Mix, mix mixing, sterilizing, solid beverage is made.
Embodiment 3
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：120 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 4 parts of chalybeates, 0.2 part of folic acid, 100 parts of DHA, 2769 parts
D-sorbite, 3 parts of citric acids, 0.6 part of acesulfame potassium, 3 parts of flavoring essences.
4 parts of chalybeates, 0.2 part of folic acid, 100 parts of DHA, 2769 parts of D-sorbites, 3 parts of citric acids, 0.6 part of acesulfame potassium are mixed
Close, stir and evenly mix, add 120 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders and the stirring of 3 parts of flavoring essences, mixing mix,
Sterilizing, is made solid beverage.
Embodiment 4
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：180 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 6 parts of chalybeates, 0.3 part of folic acid, 150 parts of DHA, 4154 parts
D-sorbite, 4.5 parts of citric acids, 0.9 part of acesulfame potassium, flavoring essence 0.1-20 parts.
6 parts of chalybeates, 0.3 part of folic acid, 150 parts of DHA, 4154 parts of D-sorbites, 4.5 parts of citric acids, 0.9 part of acesulfame potassium are mixed
Close, stir and evenly mix, add 180 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders and 4.5 parts of flavoring essence stirrings, mixing are mixed
Even, sterilizing, is made solid beverage.
Embodiment 5
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：The haematococcus pluvialis spore powder with crushed sporoderm of 300 parts of water-soluble processing, 4 parts of chalybeates, 0.2 folic acid, 150 parts of DHA, 539 parts
D-sorbite, 5 parts of magnesium stearates, 1 part of citric acid, 1 part of flavoring essence.
By 4 parts of chalybeates, 0.2 part of folic acid, 150 parts of DHA, 539 parts of D-sorbites, 5 parts of magnesium stearates, 1 part of citric acid mix,
Stir and evenly mix, the haematococcus pluvialis spore powder with crushed sporoderm for adding the water-soluble processing of 1 part of flavoring essence and 300 parts mix, stir and evenly mix,
Tablet is made in sterilizing, tabletting.
Embodiment 6
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：The haematococcus pluvialis spore powder with crushed sporoderm of 500 parts of water-soluble processing, 6 parts of chalybeates, 0.3 part of folic acid, 150 parts of DHA, 810
Part D-sorbite, 7.5 parts of magnesium stearates, 1.5 parts of citric acids, 1.5 parts of flavoring essences.
By 6 parts of chalybeates, 0.3 part of folic acid, 150 parts of DHA, 810 parts of D-sorbites, 7.5 parts of magnesium stearates, 1.5 parts of citric acids
Stir and evenly mix, the haematococcus pluvialis spore powder with crushed sporoderm for adding 1.5 parts of essence and 500 parts of water-soluble processing mixes, stirs and evenly mixs, gone out
Tablet is made in bacterium, tabletting.
Embodiment 7
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：120 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 4 parts of chalybeates, 0.2 part of folic acid, 150 parts of DHA, 719 parts of mountains
Pears sugar alcohol, 5 parts of magnesium stearates, 1 part of citric acid, 1 part of flavoring essence.
By 4 parts of chalybeates, 0.2 part of folic acid, 150 parts of DHA, 719 parts of D-sorbites, 5 parts of magnesium stearates, 1 part of citric acid mix,
After stirring and evenly mixing, add 120 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders and 1 part of flavoring essence mixes, stirs and evenly mixs, gone out
Tablet is made in bacterium, tabletting.
Embodiment 8
A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment, include following components by mass fraction
Mix：250 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 8 parts of chalybeates, 0.4 part of folic acid, 300 parts of DHA, 1440 parts
D-sorbite, 9 parts of magnesium stearates, 2 parts of citric acids, 2 parts of flavoring essences.
8 parts of chalybeates, 0.4 part of folic acid, 300 parts of DHA, 1440 parts of D-sorbites, 9 parts of magnesium stearates, 2 parts of citric acids are mixed
After closing, stirring and evenly mixing, add 250 parts of Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders and 2 parts of flavoring essences mixing, stirrings are mixed
Tablet is made in even, sterilizing, tabletting.
Finally it should be noted that the invention is not restricted to above example, there can also be many variations.This area it is general
All deformations that logical technical staff directly can export or associate from present disclosure, it is considered as the present invention's
Protection domain.
Claims (8)
1. the infertile Astaxanthin In Haematococcus Pluvialis product formula of a kind of auxiliary treatment, it is characterised in that by mass fraction bag
Following components are included to mix：2-20 part Astaxanthin In Haematococcus Pluvialis, 1-10 part chalybeates, 0.2-0.8 part folic acid, 20-200 parts
DHA。
2. the infertile Astaxanthin In Haematococcus Pluvialis product formula of a kind of auxiliary treatment, it is characterised in that by mass fraction bag
Following components are included to mix：The haematococcus pluvialis spore powder with crushed sporoderm of the water-soluble processing of 40-4000 parts, 1-10 part chalybeates, 0.2-
0.8 part of folic acid, 20-200 parts DHA, 40-9900 part sweetener, 0.05-10 part acids, 0.01-3 part acesulfame potassiums, 0.1-20 parts
Flavoring essence.
3. the infertile Astaxanthin In Haematococcus Pluvialis product formula of a kind of auxiliary treatment, it is characterised in that by mass fraction bag
Following components are included to mix：20-1000 part Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 1-10 part chalybeates, 0.2-0.8 parts
Folic acid, 20-200 parts DHA, 60-9900 part sweetener, 0.05-10 part acids, 0.01-3 part acesulfame potassiums, 0.1-20 parts eat
Essence.
4. the infertile Astaxanthin In Haematococcus Pluvialis product formula of a kind of auxiliary treatment, it is characterised in that by mass fraction bag
Following components are included to mix：The haematococcus pluvialis spore powder with crushed sporoderm of the water-soluble processing of 40-4000 parts, 1-10 part chalybeates, 0.2-
0.8 part of folic acid, 20-200 parts DHA, 120-4900 part sweetener, 0.2-50 part magnesium stearates, 0.5-10 part acids, 0.1-10
Part flavoring essence.
5. the infertile Astaxanthin In Haematococcus Pluvialis product formula of a kind of auxiliary treatment, it is characterised in that by mass fraction bag
Following components are included to mix：20-1000 part Astaxanthin In Haematococcus Pluvialis water solubility microcapsule powders, 1-10 part chalybeates, 0.2-0.8 parts
Folic acid, 20-200 parts DHA, 120-4900 part sweetener, 0.2-50 part magnesium stearates, 0.5-10 part acids, 0.1-10 parts food
Use essence.
6. a kind of infertile Astaxanthin In Haematococcus Pluvialis product of auxiliary treatment according to claim any one of 1-5 is matched somebody with somebody
Side, it is characterised in that：The chalybeate is any of ferrous sulfate, ferrous lactate, ferrous fumarate or two or more.
7. a kind of infertile Astaxanthin In Haematococcus Pluvialis product of auxiliary treatment according to claim any one of 2-5 is matched somebody with somebody
Side, it is characterised in that：The acid is any of citric acid, lactic acid, malic acid or two or more, and the sweetener is
Any of D-sorbite, xylitol, acesulfame potassium, Abbas's sweet tea are two or more.
8. a kind of infertile Astaxanthin In Haematococcus Pluvialis product of auxiliary treatment according to claim any one of 1-5 is matched somebody with somebody
Side, it is characterised in that can be made into solid beverage and tablet after the mixing of each component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710975550.9A CN107536055A (en) | 2017-10-19 | 2017-10-19 | A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710975550.9A CN107536055A (en) | 2017-10-19 | 2017-10-19 | A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107536055A true CN107536055A (en) | 2018-01-05 |
Family
ID=60967761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710975550.9A Pending CN107536055A (en) | 2017-10-19 | 2017-10-19 | A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107536055A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110115379A (en) * | 2018-02-06 | 2019-08-13 | 云南绿A生物工程有限公司 | Skin care compositions and its preparation method and application |
| CN110693032A (en) * | 2019-09-18 | 2020-01-17 | 孙启城 | Food containing L-carnitine and haematococcus pluvialis |
| CN111972586A (en) * | 2020-08-17 | 2020-11-24 | 同方药业集团有限公司 | Astaxanthin nutrient solid beverage |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1039888B1 (en) * | 1997-12-09 | 2003-02-19 | Astacarotene Ab | Method of increasing the production and improving the quality of semen |
| CN101057677A (en) * | 2007-04-27 | 2007-10-24 | 李卫平 | Xinxi nutrient supplement |
| CN104187679A (en) * | 2014-09-13 | 2014-12-10 | 昆明元正生物科技有限公司 | Haematococcus pluvialis maca health product and preparation method thereof |
| CN104856051A (en) * | 2015-04-10 | 2015-08-26 | 杭州鑫伟低碳技术研发有限公司 | Method for producing microcapsules of astaxanthin powder by utilizing haematococcus pluvialis |
| CN106135907A (en) * | 2015-04-11 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | A kind of alimentation composition contributing to resisting fatigue |
| CN106668507A (en) * | 2016-12-29 | 2017-05-17 | 昭远制药(上海)有限公司 | Medicine for curing male infertility and preparation method thereof |
-
2017
- 2017-10-19 CN CN201710975550.9A patent/CN107536055A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1039888B1 (en) * | 1997-12-09 | 2003-02-19 | Astacarotene Ab | Method of increasing the production and improving the quality of semen |
| CN101057677A (en) * | 2007-04-27 | 2007-10-24 | 李卫平 | Xinxi nutrient supplement |
| CN104187679A (en) * | 2014-09-13 | 2014-12-10 | 昆明元正生物科技有限公司 | Haematococcus pluvialis maca health product and preparation method thereof |
| CN104856051A (en) * | 2015-04-10 | 2015-08-26 | 杭州鑫伟低碳技术研发有限公司 | Method for producing microcapsules of astaxanthin powder by utilizing haematococcus pluvialis |
| CN106135907A (en) * | 2015-04-11 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | A kind of alimentation composition contributing to resisting fatigue |
| CN106668507A (en) * | 2016-12-29 | 2017-05-17 | 昭远制药(上海)有限公司 | Medicine for curing male infertility and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110115379A (en) * | 2018-02-06 | 2019-08-13 | 云南绿A生物工程有限公司 | Skin care compositions and its preparation method and application |
| CN110693032A (en) * | 2019-09-18 | 2020-01-17 | 孙启城 | Food containing L-carnitine and haematococcus pluvialis |
| CN111972586A (en) * | 2020-08-17 | 2020-11-24 | 同方药业集团有限公司 | Astaxanthin nutrient solid beverage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090047304A1 (en) | Composition For Body Fat Reduction | |
| EP1938810B1 (en) | Ameliorating agent for metabolic syndrome | |
| EP1588711A1 (en) | Composition trapping radicals in organism | |
| JP5909795B2 (en) | Antiallergic composition | |
| JP2021008447A (en) | Health keeping product composition applicable to adult female, elderly, and sub-healthy people | |
| KR101323904B1 (en) | Novel use of organic compounds | |
| CN107536055A (en) | A kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment | |
| CN109619566A (en) | A kind of nutraceutical for alleviating asthenopia | |
| JP2009215170A (en) | Composition for improving metabolism in energy production | |
| WO2008059965A1 (en) | Agent for alleviating or preventing stress symptoms and agent for improving mental conditions | |
| JP2006347927A (en) | Fatigue-improving agent | |
| JP6235779B2 (en) | Folic acid-containing composition and method for stabilizing folic acid | |
| WO2019177139A1 (en) | Composition for improving skin conditions | |
| CN107439866A (en) | Matrimony vine chickpea plant nutrients beverage and its preparation technology | |
| JP2002047193A (en) | Composition for prophylaxis or treatment of allergic dermatitis | |
| JP2020176094A (en) | Composition for alleviating symptoms of overactive bladder | |
| CN110140950A (en) | One kind having anti-oxidation function composition and preparation method thereof | |
| KR20020071152A (en) | Functional food composition and a process thereof | |
| CN109954052A (en) | A kind of composition with antioxidant activity | |
| CN108041595A (en) | A kind of infertile composition of auxiliary treatment | |
| DE602004010741T2 (en) | Use of monosaccharide phosphates to improve intestinal function | |
| JP2018201487A (en) | Composition for fatigue recovery and/or prevention of fatigue accumulation | |
| CN109331022B (en) | Composition for improving female ovarian function and female skin and preparation process thereof | |
| JP2002029984A (en) | Oral composition | |
| JP2006158214A (en) | Placental extract powder-formulated food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180105 |